Homopiperidine derivatives as NK-1 antagonists

ABSTRACT

The present disclosure relates to chemical compounds and their use in human therapy. In a specific embodiment, compounds of Formula (I) or an isomer, a pharmaceutically acceptable salt or solvate thereof or a pharmaceutically acceptable formulation comprising said compounds  
                 
useful for the treatment or prevention of conditions mediated by tachykinins and/or selective inhibition of serotonin reuptake transporter protein. The compounds act as dual NK-1 antagonists and selective serotonin reuptake inhibitors.

CROSS-REFERENCE TO RELATED APPLICATIONS

This is a non-provisional application which claims the benefit of U.S. Provisional Application No. 60/589,729 filed Jul. 20, 2004.

FIELD OF DISCLOSURE

The present disclosure relates to novel chemical compounds and their use in human therapy. A particular embodiment relates to homopiperidine derivatives and to pharmaceutical compositions comprising said derivatives useful for the treatment of conditions mediated by tachykinins and/or selective inhibition of serotonin reuptake transporter protein

BACKGROUND OF THE DISCLOSURE

Depression is a debilitating disease causing significant mortality and affecting up to ten percent of the population. Selective serotonin reuptake inhibitors (SSRI's) have proven to be effective in treating depression, but have the disadvantages of delayed onset of antidepressant activity, limited efficacy and significant side effects. See Novel strategies for pharmacotherapy of depression, K. A. Maubach, N. M. J. Rupniak, M. S. Kramer, and R. G. Hill, Current Opinion in Chemical Biology 1999, 3, 491-499. Another class of clinically effective antidepressants are substance P (SP) antagonists which show high affinity and selectivity for the neurokinin 1 (NK-1) receptor. Robust antidepressant activity has been reported for two NK-1 antagonists, MK-869 (M. S. Kramer, et al., Science 1998, 281 1640) and CP-122,721 (T. J. Rosen, et al., Bioorganic and Medicinal Chemistry Letters 1998, 8, 28 and CNS Drug News, December, 2000, 24). NK₁ antagonists offer an alternative approach for treating depression in patients that respond poorly to the SSRI's and other available drugs.

The first dual NK-1 antagonists-serotonin reuptake inhibitors were described by Ryckmans et al. [Bioorganic and Medicinal Chemistry Letters 2002, 12, 261-264]. Ryckmans discloses phenoxy acetamides and phenyl propionamides as NK-1 antagonists and serotonin reuptake inhibitors and the potential of a new generation of antidepressants.

U.S. Pat. No. 6,136,824 discloses piperidinyl-propane-2-derivatives which exhibit both NK-1 receptor antagonism and/or selective serotonin reuptake inhibitor (hereinafter referred to as SSRI) activity.

International Application WO2004/005256 discloses cyclic amine derivatives that exhibit both NK-1 receptor antagonism and/or SSRI activity.

International Application WO2004/005255 discloses N-benzyl-3-phenyl-3-heterocyclic-propionamide compounds as tachykinin and/or serotonin reuptake inhibitors.

The compounds of the present disclosure have activity as NK-1 antagonists and/or also have activity as selective serotonin reuptake inhibitors. Thus, they are of use in the treatment of conditions mediated by tachykinins and/or selective inhibition of the serotonin reuptake transporter protein. One aspect of the class of compounds of the present disclosure exhibit both NK-1 receptor antagonist and SSRI activity.

Thus, novel dual NK-1 antagonists and SSRI inhibitors effective for the treatment of numerous disorders, such as central nervous system disorders, would be advantageous.

SUMMARY

A class of compounds is provided that exhibit dual NK-1 antagonists and/or serotonin reuptake inhibitors of Formula (I)

or an isomer, a pharmaceutically acceptable salt or solvate thereof wherein

-   -   R¹, R², R³, R⁴, R⁵ and R⁶ are independently H, C₁₋₄ alkyl, C₁₋₄         alkoxy, fluoro C₁₋₄ alkyl, halo or cyano; and     -   R⁷ is H, C₁₋₆ alkyl, benzyl, C₃₋₆ cycloalkyl, or C₃₋₆ cycloalkyl         C₁₋₃ alkyl;

The present compounds antagonize NK-1 receptors, that is; they bind to the receptors such that Substance P and other tachykinins are inhibited from binding to the NK-1 receptors. The compounds of this disclosure are useful as therapeutic agents in conditions characterized by excessive Substance P and other tachykinins expression, and thus, this disclosure provides methods of treating a subject afflicted with such a disorder.

DETAILED DESCRIPTION

The instant compounds are useful in the treatment of central nervous system disorders and a myriad of other conditions by virtue of their activity as NK-1 receptor antagonists and/or their activity as selective serotonin reuptake inhibitors.

A compound is provided of Formula (I) or an isomer, a pharmaceutically acceptable salt or solvate thereof:

wherein R¹, R², R³, R⁴, R⁵ and R⁶ are independently H, C₁₋₄ alkyl, C₁₋₄ alkoxy, fluoro C₁₋₄ alkyl, halo or cyano; and R⁷ is H, C₁₋₆ alkyl, benzyl, C₃₋₆ cycloalkyl, or C₃₋₆ cycloalkyl C₁₋₃ alkyl.

“Alkyl” means saturated carbon chains, branched or unbranched having the specified number of carbons. The term “(C_(x)-C_(y)) alkyl” where x and y are integers means an alkyl group having from x to y carbon atoms. The term “C₁₋₄ alkyl” means an alkyl group having from 1 to 4 carbon atoms and includes, without limitation groups such as methyl, ethyl, n-propyl, isopropyl, methylpropyl, n-butyl, t-butyl, isobutyl and sec-butyl. Derived expressions such as C₁₋₄ alkoxy are to be construed accordingly.

The term “C₃₋₆ cycloalkyl” as used herein means a carbon cyclic ring system having from 3 to 6 carbon atoms and includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like. The term “fluoro C₁₋₄ alkyl” means a C₁₋₄ group in which one or more (in particular 1-3) hydrogen atoms have been replaced by fluorine atoms and includes without limitation trifluoromethyl, fluoromethyl, trifluoromethylethyl, trifluoromethylpropyl and the like.

“Halo” or “halogen” as used herein includes fluorine, chlorine, bromine, and iodine.

References hereinafter to a compound according to the present disclosure include both compounds of formula (1) and their pharmaceutically acceptable salts and solvates. The solvates may for example be hydrates.

Preferably R⁷ is hydrogen.

In another preferred embodiment, R⁴ and R⁵ are independently CH₃ and R⁶ is hydrogen.

According to yet another embodiment, R⁴ and R⁵ are independently CF₃ and R⁶ is hydrogen.

In still another preferred embodiment, R⁴ and R⁵ are independently CF₃ and are each in the meta position with respect to —CH₂O— and R⁶ is hydrogen.

Specific compounds according to the present disclosure are:

isomers A and B of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylazepane;

isomers A and B of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-methyl-4-phenylazepane;

isomers A and B of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-ethyl-4-phenylazepane;

isomer A of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-(cyclopropylmethyl)-4-phenylazepane;

isomer A of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-benzyl-4-phenylazepane;

isomer A of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-cyclopentyl-4-phenylazepane;

isomer A of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-isopropyl-4-phenylazepane;

isomer B of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-(cyclopropylmethyl)-4-phenylazepane;

isomer B of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-cyclopentyl-4-phenylazepane; and

isomer B of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-benzyl-4-phenylazepane.

As the compounds of the present disclosure possess asymmetric carbon atoms, the present invention includes all “isomers” which means all possible stereoisomers geometric isomers, diastereoisomers, enantiomers, anomers and optical isomers of the compounds of Formula I as described herein and in the claims. The use of a single designation such as (R) or (S); or isomer A or isomer B is intended to include mostly one stereoisomer at the position indicated. Mixtures of isomers can be separated into individual isomers according to methods which are known per se, e.g. fractional crystallization, adsorption chromatography or other suitable separation processes. Resulting racemates can be separated into antipodes in the usual manner after introduction of suitable salt-forming groupings, e.g. by forming a mixture of diastereosiomeric salts with optically active salt-forming agents, separating the mixture into diastereomeric salts and converting the separated salts into the free compounds. The possible enantiomeric forms may also be separated by fractionation through chiral high pressure liquid chromatography columns.

The compounds may exist in the form of pharmaceutically acceptable salts. Such salts may include addition salts with inorganic acids such as, for example, hydrochloric acid and sulfuric acid, and with organic acids such as, for example, acetic acid, citric acid, methanesulfonic acid, toluenesulfonic acid, tartaric acid and maleic acid. Further, in case the compounds contain an acidic group, the acidic group may exist in the form of alkali metal salts such as, for example, a potassium salt and a sodium salt; alkaline earth metal salts such as, for example, a magnesium salt and a calcium salt; and salts with organic bases such as a triethylammonium salt and an arginine salt. In the case of a sublingual formulation a saccharin salt or maleate salt may be of particular benefit. The compounds of the present disclosure may be hydrated or non-hydrated.

As described in International Applications WO 2004/005255 and WO2004/005256, by virtue of their activity as tachykinin (especially NK-1 receptor) antagonists, the compounds of formula (I) are of value in the treatment of a wide variety of clinical conditions which are characterized by the presence of an excess tachykinin, in particular, substance P activity.

As previously stated, compounds of the present disclosure are useful in the treatment of central nervous system disorders, particularly in the treatment or prevention of depression and/or in the treatment of anxiety.

Depression includes, but, is not limited to Major Depressive Disorders (MDD), including bipolar depression, unipolar depression, single or recurrent major depressive episodes, recurrent brief depression, catatonic features, melancholic features including feeding disorders, such as anorexia, weight loss, atypical features, anxious depression, or postpartum onset.

Other central nervous system disorders encompassed within the term MDD include neurotic depression, post-traumatic stress disorders (PTSD) and social phobia; with early or late onset dementia of the Alzheimer's type, with depressed mood; vascular dementia with depressed mood; mood disorders and tolerance induced by drugs such as alcohol, amphetamines, cocaine, inhalants, opioids, sedatives, anxiolytics and other substances; schizoaffective disorder of the depressed type; and adjustment disorder with depressed mood.

The compounds are also useful in the treatment or prevention of schizophrenic disorders including paranoid schizophrenia, disorganized schizophrenia, catatonic schizophrenia, undifferentiated schizophrenia, residual schizophrenia.

The term anxiety includes, but is not limited to disorders, such as panic disorders, agoraphobia, phobias, obsessive-compulsive disorder, stress disorders including post-traumatic stress disorders, generalized anxiety disorders, acute stress disorders and mixed anxiety-depression disorders.

Compounds of the disclosure are also useful in the treatment or prevention of the cognitive disorders. Cognitive disorders include dementia, amnesia disorders and cognitive disorders not otherwise specified.

Furthermore, the compounds are also useful as memory and/or cognition enhancers in healthy humans with no cognitive and/or memory deficit.

In addition, the compounds are useful as analgesics. In particular, they are useful in the treatment of traumatic pain such as postoperative pain; chronic pain such as arthritic pain such as occurring in osteo-, rheumatoid or psoriatic arthritis; neuropathic pain such as post-herpetic neuralgia, trigeminal neuralgia, segmental or intercostal neuralgia, fibromyalgia, peripheral neuropathy, diabetic neuropathy, chemotherapy-induced neuropathy, AIDS-related neuropathy, various forms of headache such as migraine, acute or chronic tension headache, cluster headaches, maxillary sinus pain, cancer pain; pain of bodily origin; gastrointestinal pain; sport's injury pain; dysmennorrhoea; menstrual pain; meningitis; musculoskeletal pain; low back pain e.g. spinal stenosis; prolapsed disc; sciatica; angina; ankylosing spondyolitis; gout; burns; scar pain; itch and thalamic pain such as post stroke thalamic pain.

The compounds are also useful in the treatment of sleep disorders including insomnia, sleep apnea, narcolepsy, and circadian rhymic disorders.

Compounds of the present disclosure are also useful as anti-inflammatory agents. In particular, they are useful in the treatment of inflammation in asthma, influenza and chronic bronchitis; in the treatment of inflammatory diseases of the gastrointestinal tract such as Crohn's disease, ulcerative colitis, inflammatory bowel disease and non-steroidal anti-inflammatory drug induced damage; inflammatory diseases of the skin such as herpes and eczema; inflammatory diseases of the bladder such as cystitis and urge incontinence; and eye and dental inflammation.

Compounds of the disclosure are also useful in the treatment of allergic disorders, in particular allergic disorders of the skin such as urticaria, and allergic disorders of the airways such as rhinitis.

The compounds are also useful in the treatment of emesis, i.e. nausea, retching and vomiting. Emesis includes acute emesis and anticipatory emesis. The compounds of the disclosure are useful in the treatment of emesis however induced. For example, emesis may be induced by drugs such as cancer chemotherapeutic agents such as alkylating agents, e.g. cyclophosphamide and chlorambucil; cytotoxic antibiotics, e.g. dactinomycin, doxorubicin, mitomycin-C and bleomycin; anti-metabolites, e.g. cytarabine, methotrexate and 5-fluorouracil; vinca alkaloids, e.g. etoposide, vinblastine and vincristine; and others such as cisplatin, dacarbazine, procarbazine and hydroxyurea; and combinations thereof; radiation sickness; radiation therapy, e.g. irradiation of the thorax or abdomen, such as in the treatment of cancer; poisons; toxins such as toxins caused by metabolic disorders or by infection, e.g. gastritis, or released during bacterial or viral gastrointestinal infection; pregnancy; vestibular disorders, such as motion sickness, vertigo, dizziness and Meniere's disease; post-operative sickness; gastrointestinal obstruction; reduced gastrointestinal motility; visceral pain, e.g. myocardial infarction or peritonitis; increased intercranial pressure; decreased intercranial pressure (e.g. altitude sickness); opioid analgesics, such as morphine; and gastro-oesophageal reflux disease (GERD) such as erosive GERD and symptomatic GERD or non erosive GERD, acid indigestion, over-indulgence of food or drink, acid stomach, sour stomach, heartburn, such as episodic heartburn, nocturnal heartburn, and meal-induced heartburn, dyspepsia and functional dyspepsia.

The compounds are also useful in premenstrual dysphoric disorder (PMDD), in chronic fatigue syndrome and multiple sclerosis.

A compound is provided of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in therapy, in particular in human medicine.

In an alternative or further aspect there is provided a method for the treatment of a mammal, including man, in particular, in the treatment of conditions mediated by tachykinins, including substance P and other neurokinins and/or by selective inhibition of the serotonin reuptake transporter protein comprising administration of an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

In another embodiment there is provided a method for the treatment of a mammal, including man, in particular in the treatment of depression and/or anxiety which method comprises administration of an effective amount of a compound of formula (1) or a pharmaceutically acceptable salt or solvate thereof.

The compounds of the disclosure can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups and emulsions. The compounds may also be administered intravenously, intraperitoneally, subcutaneously, or intramuscularly, all using dosage forms well known to those skilled in the pharmaceutical arts. The compounds can be administered alone, but generally will be administered with a pharmaceutical carrier selected upon the basis of the chosen route of administration and standard pharmaceutical practice. Compounds of this disclosure can also be administered in intranasal form by topical use of suitable intranasal vehicles, or by transdermal routes, using transdermal skin patches. When compounds of this disclosure are administered transdermally the dosage will be continuous throughout the dosage regimen.

The dosage and dosage regimen and scheduling of a compounds of the present disclosure must in each case be carefully adjusted, utilizing sound professional judgment and considering the age, weight and condition of the recipient, the route of administration and the nature and extent of the disease condition. In accordance with good clinical practice, it is preferred to administer the instant compounds at a concentration level which will produce effective beneficial effects without causing any harmful or untoward side effects.

The instant compounds may be synthesized according to the general schemes provided below. Variables provided in the scheme below are defined in accordance with the description of compounds of the above Formulae unless otherwise specified.

The synthesis of compounds of formula I is shown in Scheme 1. Addition of appropriately substituted phenyl magnesium bromide or chloride to ethyl enol ether 1 provided α,β-unsaturated ketone 2, which underwent 1,4-conjugated addition with hydrogen cyanide to furnish cyano-ketone 3. Ketalization of 3 was achieved with ethylene glycol in the presence of an acid catalyst, and the resulting ketal 4 was reduced with di-isobutylaluminum hydride to give aldehyde 5. This aldehyde was further reduced with sodium borohydride to afford alcohol 6, which was converted to 7 by treatment with sodium hydride and appropriately substituted benzyl bromide. The conversion of 7 to ketone 8 was carried out under acidic conditions such as hydrochloric acid in THF. Schmidt rearrangement of ketone 8 with hydrazoic acid in trifluoroacetic acid gave lactam 9 (A. G. Schultz et. al. J. Med. Chem. 1996, 39, 1956-1966). Lactam 9 was reduced with borane-THF complex to furnish amines 10. Compounds of formula I were obtained from 10 via reductive alkylation with appropriate aldehydes or ketones.

INTERMEDIATE 1 3-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-3-phenylcyclohexanone

Step A: 3-phenylcyclohex-2-enone

At 0° C., 3-ethoxycyclohex-2-enone (2 g, 14.3 mmol) in THF (2 mL) was added phenylmagnesium bromide (1.0 M solution in THF, 15.0 mL) slowly. After the addition, the reaction mixture was warmed up to room temperature and stirred for 1 hr. Then 1N HCl solution (15.16 mL) was added to quench the reaction and the organic layer was separated. The aqueous layer was extracted with dichloromethane 3 times. The combined organic layers were dried over magnesium sulfate, filtered and concentrated to give the title compound as yellow solid (quantitative yield). ¹H NMR (400 MHz, CDCl₃) δ 2.16 (2H, dt, J=4, 12 Hz), 2.48 (2H, t, J=8 Hz), 2.77 (2H, dt, J=2, 6 Hz), 6.41 (1H, t, J=2 Hz), 7.39-7.41 (3H, m), 7.52-7.54 (2H, m).

Step B: 3,3-ethylenedioxy-1-phenylcyclohexanecarbonitrile

A mixture of 3-phenylcyclohex-2-enone (14.3 mmol), potassium cyanide (1.92 g) and trimethylamine hydrochloride (2.06 g, 21.5 mmol) in H₂O (10 mL) and DMF (57 mL) was heated at 93° C. for 6 hr. After cooling down to room temperature, saturated sodium bicarbonate was added and the organic layer was separated. The aqueous layer was extracted with diethyl ether 3 times. The combined organic layers were washed with saturated sodium chloride solution, dried over magnesium sulfate, filtered and concentrated under vacuum to get 2.62 g of the crude 3-oxo-1-phenylcyclohexanecarbonitrile which was directly taken to the next step without further purification.

The mixture of 3-oxo-1-phenylcyclohexanecarbonitrile (2.62 g), ethylene glycol (3.65 mL) and pyridinium p-toluene sulfonate (1 spatula) in benzene (40 mL) was stirred at 111° C. with Dean-Stark apparatus overnight. After cooling down to room temperature, the mixture was washed with saturated sodium bicarbonate and the organic layer was separated. The aqueous layer was extracted with dichloromethane 3 times and the combined organic layers were dried over magnesium sulfate, filtered and concentrated under vacuum. The crude material was purified by Flash Chromatography with from 25% ethyl acetate/75% hexane to 30% ethyl acetate/70% hexane over 20 minutes. The title compound was obtained as a white solid (1.66 g, 48% yield in 2 steps). ¹H NMR (400 MHz, CDCl₃) δ 1.56 (1H, dt, J=4, 16 Hz), 1.70-1.79 (1H, m), 1.89-1.96 (3H, m), 2.06-2.28 (3H, m), 3.89-3.97 (2H, m), 4.03-4.12 (2H, m), 7.28-7.32 (1H, m), 7.36-7.39 (2H, m), 7.48-7.51 (2H, m). HPLC purity (retention time): 95% (1.62 min, method C). MS: 266.37 (M+Na⁺).

Step C: 3,3-ethylenedioxy-1-phenylcyclohexanecarbaldehyde

At −78° C., 3-ethylenedioxy-1-phenylcyclohexanecarbonitrile (1.66 g, 6.83 mmol) in toluene (20 mL) was added DIBAL-H (1.0 M solution in toluene, 8.88 mL) slowly and was stirred for 1 hr. The reaction mixture was warmed up to room temperature and was added 1N HCl solution (2.60 mL) and was stirred for 1 hr. Saturated sodium bicarbonate was added to quench the reaction and the organic layer was separated. The aqueous layer was extracted with dichloromethane 3 times and the combined organic layers were dried over magnesium sulfate, filtered and concentrated under vacuum. The crude material was purified by filtering through a short silica gel pad with dichloromethane to give the title compound as a white sticky oil (1.43 g, 85% yield). ¹H NMR (400 MHz, CDCl₃) δ 1.32-1.40 (1H, m), 1.46-1.54 (1H, m), 1.72-1.86 (3H, m), 2.08 (1H, d, J=16 Hz), 2.59-2.67 (2H, m), 3.94-4.07 (4H, m), 7.15-7.36 (5H, m), 9.36 (1H, d, J=4 Hz).

Step D: (3,3-ethylenedioxy-1-phenylcyclohexyl)methanol

To a solution of methyl 3,3-ethylenedioxy-1-phenylcyclohexanecarbaldehyde (1.43 g, 5.81 mmol) in methanol (25 mL) at 0° C. was added sodium borohydride (221 mg) in portions, and the resulting suspension was stirred at room temperature overnight. The reaction was quenched with saturated sodium bicarbonate and methanol was removed under vacuum. The aqueous layer was extracted with dichloromethane 3 times. The combined organic layers were dried over magnesium sulfate, filtered and concentrated in vacuo to give the title compound as clear colorless sticky oil (1.25 g, 87% yield). ¹H NMR (400 MHz, CDCl₃) δ 1.48-1.81 (7H, m), 1.88 (1H, d, J=16 Hz), 2.06 (1H, d, J=12 Hz), 2.22 (1H, d, J=12 Hz), 3.73-4.06 (5H, m), 7.15-7.25 (2H, m), 7.31-7.38 (3H, m). HPLC purity (retention time): 85% (1.44 min, method C). MS: 271.40 (M+Na⁺).

Step E: 1-(((3,3-ethylenedioxy-1-phenylcyclohexyl)methoxy)methyl)-3,5-bis(trifluoromethyl)benzene

To a solution of ((3,3-ethylenedioxy-1-phenylcyclohexyl)methanol (726 mg, 2.93 mmol) and 3,5-(bis-trifluoromethyl)benzyl bromide (1.08 mL) in DMF (6 mL) at 0° C. was added sodium hydride (95% oil dispersion, 148 mg) and the resulting suspension was stirred at room temperature for 2 hr. Saturated sodium bicarbonate was added to quench the reaction and the organic layer was separated. The aqueous layer was extracted with dichloromethane 3 times and the combined organic layers were dried over magnesium sulfate, filtered and concentrated under vacuum. The crude material was purified by preparative Flash Chromatography eluting with from 10% acetone/90% hexanes to 15% acetone/85% hexanes over 20 minutes to give the title compound as clear pale yellow sticky oil (990 mg, 71% yield). ¹H NMR (400 MHz, CDCl₃) δ 1.25 (1H, m), 1.74 (4H, t, J=8 Hz), 1.90 (1H, d, J=12 Hz), 2.13 (1H, m), 2.24 (1H, d, J=16 Hz), 3.70 (2H, dd, J=8, 36 Hz), 3.91 (4H, m), 4.45 (2H, s), 7.21 (2H, t, J=8 Hz), 7.29-7.38 (4H, m), 7.53 (2H, s), 7.71 (1H, s). HPLC purity (retention time): 100% (2.34 min, method C). MS: 475.14 (M+H⁺).

Step F: 3-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-3-phenylcyclohexanone

To a solution of 1-(((3,3-ethylenedioxy-1-phenylcyclohexyl)methoxy)methyl)-3,5-bis(trifluoromethyl)benzene (990 mg, 2.09 mmol) in acetone (4 mL) at room temperature were added 1N HCl solution (3.13 mL) and the resulting mixture was stirred at reflux for 2 hr. After cooling down, saturated sodium bicarbonate and dichloromethane were added and the organic layer was separated. The aqueous layer was extracted with dichloromethane 2 times and the combined organic layers were dried over magnesium sulfate, filtered and concentrated under vacuum to give the title compound as clear pale yellow sticky oil (830 mg, 92% yield). ¹H NMR (400 MHz, CDCl₃) δ 1.60 (1H, m), 1.88 (1H, m), 2.19-2.24 (2H, m), 2.29-2.32 (2H, m), 2.85 (2H, dd, J=12, 68 Hz), 3.51 (2H, dd, J=12, 56 Hz), 4.52 (2H, dd, J=16, 18 Hz), 7.22-7.25 (1H, m), 7.32 (4H, d, J=4 Hz), 7.63 (2H, s), 7.77 (1H, s). HPLC purity (retention time): 90% (2.32 min, method C). MS: 453.37 (M+Na⁺).

INTERMEDIATES 2-3 Isomer A and Isomer B of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylazepan-2-one

The mixture of 3-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-3-phenylcyclohexanone (730 mg, 1.70 mmol) and NaN₃ solution (3.0 M in H₂O, 1.13 mL) in trifluoroacetic acid (5.6 mL) was stirred at 65° C. for 1 hr. After cooling down, the mixture was concentrated under vacuum and saturated sodium bicarbonate and dichloromethane were added and the organic layer was separated. The aqueous layer was extracted with dichloromethane 2 times and the combined organic layers were dried over magnesium sulfate, filtered and concentrated under vacuum. The crude mixture was purified by Flash Chromatography with from 30% acetone/70% hexane to 40% acetone/60% hexane over 20 minutes to mixtures of 4 isomers as white sticky oil (540 mg, 71% yield). HPLC purity (retention time): 93% (2.08 min, method C). MS: 446.11 (MH⁺).

The mixture of 4 isomers were separated by Chiral HPLC (Chiralpak AS semi-prep column, 20×250 mm, 10 um, solvents 5% EtOH/95% heptane for 83 min., 15% EtOH/85% heptane for 17 min., 5% EtOH/95% heptane for 10 min., flow rate 10 mL/min., UV 205 nm) to give isomer A (110 mg, 81% recovery) and isomer B (110 mg, 81% recovery) of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylazepan-2-one and isomer A (80 mg, 59% recovery) and isomer B (90 mg, 67% recovery) of 6-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-6-phenylazepan-2-one as white sticky oils.

Isomer A of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylazepan-2-one: Retention time is 44.02 min. with >99.9% ee. ¹H NMR (CDCl₃, 400 MHz) δ 1.72-1.80 (2H, m), 2.04 (1H, m), 2.51 (1H, d, J=16 Hz), 2.94 (1H, d, J=16 Hz), 3.10 (1H, d, J=16 Hz), 3.17 (1H, m), 3.24-3.32 (1H, m), 3.45 (2H, s), 4.46 (2H, s), 5.81 (1H, s), 7.24 (1H, t, J=8 Hz), 7.34 (2H, t, J=8 Hz), 7.47 (2H, d, J=8 Hz), 7.61 (2H, s), 7.75 (1H, s). ¹³C NMR (CDCl₃, 100 MHz) δ 25.3, 36.7, 42.9, 43.2, 44.1, 71.8, 81.0, 121.8 (quintet, J=3 Hz), 123.7 (q, J=271 Hz), 127.2, 127.5 (d, J=4 Hz), 127.6, 128.8, 132.0 (q, J=33 Hz), 141.4, 142.0, 175.9. Optical rotation, [α]_(D) ²⁴ −9.03 (c 1.77, MeCl₂). HRMS calcd for C₂₂H₂₂NO₂F₆ 446.1555 (MH⁺), found 446.1571.

Isomer B of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylazepan-2-one: Retention time is 53.38 min. with >99.8% ee. ¹H NMR (CDCl₃, 400 MHz) δ 1.73-1.81 (2H, m), 2.04 (1H, m), 2.52 (1H, d, J=12 Hz), 2.94 (1H, d, J=16 Hz), 3.10 (1H, d, J=12 Hz), 3.18 (1H, dt, J=4, 8 Hz), 3.24-3.31 (1H, m), 3.45 (2H, s), 4.46 (2H, dd, J=12, 16 Hz), 5.74 (1H, s), 7.24 (1H, t, J=8 Hz), 7.34 (2H, t, J=8 Hz), 7.47 (2H, d, J=8 Hz), 7.61 (2H, s), 7.75 (1H, s). ¹³C NMR (CDCl₃, 100 MHz) δ 25.3, 36.7, 42.9, 43.2, 44.1, 71.8, 81.0, 121.8 (quintet, J=3 Hz), 123.7 (q, J=271 Hz), 127.2, 127.5 (d, J=4 Hz), 127.6, 128.8, 132.0 (q, J=33 Hz), 141.4, 142.0, 175.9. Optical rotation, [α]_(D) ²⁴ +7.10 (c 1.69, MeCl₂). HRMS calcd for C₂₂H₂₂NO₂F₆ 446.1555 (MH⁺), found 446.1573.

EXAMPLE 1 Isomer A of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylazepane

The mixture of Isomer A of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylazepan-2-one (90 mg, 0.20 mmol) in borone.THF complex solution (1.5 M in diethyl ether, 1.08 mL) was stirred at room temperature overnight and then at 65° C. for 1 hr. After cooling down, the mixture was concentrated under vacuum and methanol (0.4 mL) and 1N HCl solution (0.4 mL) was added and the mixture was stirred at 65° C. for 2 hr. After cooling down, the mixture was concentrated under vacuum and neutralized with 1N NaOH solution and extracted with dichloromethane 3 times. The combined organic layers were dried over magnesium sulfate, filtered and concentrated under vacuum to give the product as a clear colorless sticky oil (quantitative yield).

¹H NMR (CDCl₃, 400 MHz) δ 1.65-1.73 (1H, m), 1.80-1.87 (1H, m), 1.94-2.01 (1H, m), 2.08 (1H, ddd, J=4, 8, 16 Hz), 2.31-2.37 (1H, m), 2.48 (1H, dd, J=4, 16 Hz), 2.86-3.01 (3H, m), 3.16 (1H, dd, J=4, 16 Hz), 3.42 (2H, s), 4.43 (2H, s), 7.21-7.23 (1H, m), 7.30-7.36 (4H, m), 7.55 (2H, s), 7.73 (1H, s). ¹³C NMR (CDCl₃, 100 MHz) δ 24.2, 34.0, 36.4, 43.5, 45.6, 48.2, 71.7, 81.5, 121.3 (quintet, J=3 Hz), 123.3 (q, J=271 Hz), 126.4, 126.9, 127.0 (d, J=3 Hz), 128.5, 131.5 (q, J=33 Hz), 141.2, 143.8. HPLC purity (retention time): 98% (1.87 min, method C). MS: 431.99 (MH⁺). HRMS calcd for C₂₂H₂₄NOF₆ 432.1762 (MH⁺), found 432.1767.

EXAMPLE 2 Isomer B of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylazepane

Isomer B of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylazepane was made from Isomer B of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylazepan-2-one in the same manner as described above to give the product as a clear colorless sticky oil (quantitative yield).

¹H NMR (CDCl₃, 400 MHz) δ 1.62-1.70 (1H, m), 1.77-1.84 (1H, m), 1.93-2.00 (1H, m), 2.04 (1H, ddd, J=4,8, 12 Hz), 2.30-2.35 (1H, m), 2.44 (1H, dd, J=4, 12 Hz), 2.80-2.97 (3H, m), 3.12 (1H, ddd, J=4, 8, 12 Hz), 3.41 (2H, s), 4.42 (2H, s), 7.20-7.24 (1H, m), 7.30-7.35 (4H, m), 7.54 (2H, s), 7.72 (1H, s). ¹³C NMR (CDCl₃, 100 MHz) δ 24.2, 34.0, 36.4, 43.5, 45.6, 48.2, 71.7, 81.5, 121.3 (quintet, J=3 Hz), 123.3 (q, J=271 Hz), 126.4, 126.9, 127.0 (d, J=3 Hz), 128.5, 131.5 (q, J=33 Hz), 141.2, 143.8. HPLC purity (retention time): 98% (1.87 min, method C). MS: 431.98 (MH⁺). HRMS calcd for C₂₂H₂₄NOF₆ 432.1762 (MH⁺), found 432.1774.

EXAMPLE 3 Isomer A of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-methyl-4-phenylazepane

The mixture of Isomer A of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylazepane (3 mg), paraformaldehyde (3 mg) and formic acid (2.2 mg) in chloroform (0.1 mL) was stirred at 65° C. for overnight. After cooling down, the mixture was concentrated under vacuum and filtered through anion exchange cartridge to get rid of formic acid. The crude product was purified by prep TLC with 10% methanol/89% dichloromethane/1% NH₄OH to give the product as a clear sticky oil (2 mg, 67% yield).

¹H NMR (CDCl₃, 400 MHz) δ 1.67-1.74 (1H, m), 1.83-1.91 (1H, m), 2.05-2.23 (3H, m), 2.38 (3H, s), 2.42-2.61 (3H, m), 2.79 (2H, m), 3.45 (2H, s), 4.44 (2H, s), 7.22 (1H, t, J=4 Hz), 7.32 (4H, d, J=4 Hz), 7.55 (2H, s), 7.73 (1H, s). ¹³C NMR (CDCl₃, 125 MHz) δ 23.4, 29.8, 34.9, 45.5, 46.7, 53.3, 60.2, 71.8, 81.1, 121.3 (quintet, J=3.75 Hz), 123.4 (q, J=271 Hz), 126.3, 126.8, 127.1, 128.4, 131.6 (q, J=32.5 Hz), 141.4, 145.7. HPLC purity (retention time): 98% (1.81 min, method C). MS: 446.04 (MH⁺). HRMS calcd for C₂₃H₂₆NOF₆ 446.1919 (MH⁺), found 446.1916.

EXAMPLE 4 Isomer B of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-methyl-4-phenylazepane

Isomer B of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-methyl-4-phenylazepane was made from Isomer B of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylazepane in the same manner as described above to give the product as a clear sticky oil (2 mg, 67% yield).

¹H NMR (CDCl₃, 400 MHz) δ 1.67-1.74 (1H, m), 1.83-1.91 (1H, m), 2.05-2.23 (3H, m), 2.38 (3H, s), 2.42-2.61 (3H, m), 2.79 (2H, m), 3.45 (2H, s), 4.44 (2H, s), 7.22 (1H, t, J=4 Hz), 7.32 (4H, d, J=4 Hz), 7.55 (2H, s), 7.73 (1H, s). ¹³C NMR (CDCl₃, 125 MHz) δ 23.4, 29.8, 34.9, 45.5, 46.7, 53.3, 60.2, 71.8, 81.1, 121.3 (quintet, J=3.75 Hz), 123.4 (q, J=271 Hz), 126.3, 126.8, 127.1, 128.4, 131.6 (q, J=32.5 Hz), 141.4, 145.7. HPLC purity (retention time): 98% (1.82 min, method C). MS: 446.04 (MH⁺). HRMS calcd for C₂₃H₂₆NOF₆ 446.1919 (MH⁺), found 446.1929.

EXAMPLE 5 Isomer A of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-ethyl-4-phenylazepane

Isomer A of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylazepane (3 mg), in glacial acetic acid (0.05 mL) was added sodium borohydride (2 mg) in two portions. After addition, the mixture was stirred at room temperature for overnight. The mixture was concentrated under vacuum. Then saturated sodium bicarbonate and dichloromethane was added to the mixture and the organic layer was separated. The aqueous layer was extracted with dichloromethane 2 times and the combined organic layers were dried over magnesium sulfate, filtered and concentrated under vacuum to give the product as a clear colorless sticky oil (1.8 mg, 56% yield).

¹H NMR (CDCl₃, 500 MHz) δ 1.57 (3H, brd s), 1.68 (1H, m), 1.79 (1H, m), 2.02-2.10 (2H, m), 2.18 (1H, dd, J=10, 15 Hz), 2.39 (1H, m), 2.49 (4H, m), 2.73 (2H, brd s), 3.46 (2H, dd, J=5, 15 Hz), 4.44 (2H, s), 7.21 (1H, t, J=5 Hz), 7.30-7.35 (4H, m), 7.56 (2H, s), 7.73 (1H, s). ¹³C NMR (CDCl₃, 125 MHz) δ 12.3, 23.7, 29.7, 34.9, 45.6, 50.1, 52.2, 57.3, 71.7, 81.2, 121.2 (quintet, J=2.5 Hz), 123.4 (q, J=271 Hz), 126.1, 126.9, 127.1 (d, J=5 Hz), 128.3, 131.6 (q, J=32.5 Hz), 141.5, 146.3. HPLC purity (retention time): 98% (1.79 min, method C). MS: 460.08 (MH⁺). HRMS calcd for C₂₄H₂₈NOF₆ 460.2075 (MH⁺), found 460.2080.

EXAMPLE 6 Isomer B of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-ethyl-4-phenylazepane

Isomer B of 4-((3,5-bis(trifluoromethyl)benzyloxy)ethyl)-1-ethyl-4-phenylazepane was made from Isomer B of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylazepane in the same manner as described above to give the product as a clear sticky oil (2 mg, 62% yield).

¹H NMR (CDCl₃, 500 MHz) δ 1.57 (3H, brd s), 1.68 (1H, m), 1.79 (1H, m), 2.02-2.10 (2H, m), 2.18 (1H, dd, J=10, 15 Hz), 2.39 (1H, m), 2.49 (4H, m), 2.73 (2H, brd s), 3.46 (2H, dd, J=5, 15 Hz), 4.44 (2H, s), 7.21 (1H, t, J=5 Hz), 7.30-7.35 (4H, m), 7.56 (2H, s), 7.73 (1H, s). ¹³C NMR (CDCl₃, 125 MHz) δ 12.3, 23.7, 29.7, 34.9, 45.6, 50.1, 52.2, 57.3, 71.7, 81.2, 121.2 (quintet, J=2.5 Hz), 123.4 (q, J=271 Hz), 126.1, 126.9, 127.1 (d, J=5 Hz), 128.3, 131.6 (q, J=32.5 Hz), 141.5, 146.3. HPLC purity (retention time): 95% (1.81 min, method C). MS: 460.09 (MH⁺). HRMS calcd for C₂₄H₂₈NOF₆ 460.2075 (MH⁺), found 460.2075.

EXAMPLE 7 Isomer A of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-(cyclopropylmethyl)-4-phenylazepane

Mixture of isomer A of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylazepane (3 mg) and cyclopropanecarbaldehyde (1.4 mg) in methanol (0.15 mL) was stirred at room temperature for 0.5 hr, then sodium cyanoborohydride (1.0 M solution in THF, 0.02 mL) was added followed by 1 drop of trifluoroacetic acid. The mixture was stirred at room temperature for overnight and concentrated under vacuum. Then saturated sodium bicarbonate and dichloromethane was added to the mixture and the organic layer was separated. The aqueous layer was extracted with dichloromethane 2 times and the combined organic layers were dried over magnesium sulfate, filtered and concentrated under vacuum to give the product as a clear sticky oil (1.4 mg, 41% yield).

¹H NMR (CDCl₃, 400 MHz) δ 0.51 (2H, d, J=8 Hz), 1.70 (4H, m), 1.82 (1H, m), 2.02-2.23 (3H, m), 2.32-2.40 (3H, m), 2.61 (2H, m), 2.83-2.93 (2H, m), 3.46 (2H, dd, J=8, 12 Hz), 4.44 (2H, s), 7.20-7.23 (1H, m), 7.30-7.36 (4H, m), 7.56 (2H, s), 7.73 (1H, s). ¹³C NMR (CDCl₃, 125 MHz) δ 1.21, 4.2, 4.2, 22.8, 29.8, 35.0, 45.5, 50.5, 63.5, 71.8, 81.1, 121.3 (quintet, J=7.5 Hz), 123.4 (q, J=271 Hz), 126.2, 126.9, 127.1, 128.3, 131.6 (q, J=1.3 Hz), 141.4, 148.1. HPLC purity (retention time): 98% (1.86 min, method C). MS: 486.14 (MH⁺). HRMS calcd for C₂₆H₃₀NOF₆ 486.2232 (MH⁺), found 486.2251.

Examples 8 to 10 were made in the same manner as in Example 7.

EXAMPLE 8 Isomer B of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-(cyclopropylmethyl)-4-phenylazepane

¹H NMR (CDCl₃, 400 MHz) δ 0.51 (2H, d, J=8 Hz), 1.70 (4H, m), 1.82 (1H, m), 2.02-2.23 (3H, m), 2.32-2.40 (3H, m), 2.61 (2H, m), 2.83-2.93 (2H, m), 3.46 (2H, dd, J=8, 12 Hz), 4.44 (2H, s), 7.20-7.23 (1H, m), 7.30-7.36 (4H, m), 7.56 (2H, s), 7.73 (1H, s). ¹³C NMR (CDCl₃, 125 MHz) δ 1.21, 4.2, 4.2, 22.8, 29.8, 35.0, 45.5, 50.5, 63.5, 71.8, 81.1, 121.3 (quintet, J=7.5 Hz), 123.4 (q, J=271 Hz), 126.2, 126.9, 127.1, 128.3, 131.6 (q, J=1.3 Hz), 141.4, 148.1. HPLC purity (retention time): 98% (1.86 min, method C). MS: 486.14 (MH⁺). HRMS calcd for C₂₆H₃₀NOF₆ 486.2232 (MH⁺), found 486.2225.

EXAMPLE 9 Isomer A of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-benzyl-4-phenylazepane

¹H NMR (CDCl₃, 400 MHz) δ 1.62-1.72 (1H, m), 1.72-1.82 (1H, m), 2.00-2.08 (2H, m), 2.18-2.24 (1H, m), 2.30-2.36 (1H, m), 2.48-2.51 (2H, m), 2.65 (2H, m), 3.45 (2H, brd s), 3.54 (2H, brd s), 4.43 (2H, s), 7.21-7.33 (10H, m), 7.56 (2H, s), 7.73 (1H, s). HPLC purity (retention time): 90% (1.91 min, method C). MS: 522.16 (MH⁺). HRMS calcd for C₂₉H₃₀NOF₆ 522.2232 (MH⁺), found 522.2241.

EXAMPLE 10 Isomer B of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-benzyl-4-phenylazepane

¹H NMR (CDCl₃, 400 MHz) δ 1.62-1.72 (1H, m), 1.72-1.82 (1H, m), 2.00-2.08 (2H, m), 2.18-2.24 (1H, m), 2.30-2.36 (1H, m), 2.48-2.51 (2H, m), 2.65 (2H, m), 3.45 (2H, brd s), 3.54 (2H, brd s), 4.43 (2H, s), 7.21-7.33 (10H, m), 7.56 (2H, s), 7.73 (1H, s). HPLC purity (retention time): 90% (1.93 min, method C). MS: 522.16 (MH⁺). HRMS calcd for C₂₉H₃₀NOF₆ 522.2232 (MH⁺), found 522.2219.

EXAMPLE 11 Isomer A of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-isopropyl-4-phenylazepane

Mixture of isomer A of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylazepane (3 mg) and acetone (1.2 mg) in methanol (0.15 mL) was stirred at room temperature for 0.5 hr, then sodium cyanoborohydride (1.0 M solution in THF, 0.02 mL) was added followed by 1 drop of trifluoroacetic acid. The mixture was stirred at 65° C. for overnight and concentrated under vacuum. Then saturated sodium bicarbonate solution and dichloromethane was added to the mixture and the organic layer was separated. The aqueous layer was extracted with dichloromethane 2 times and the combined organic layers were dried over magnesium sulfate, filtered and concentrated under vacuum to give the product as a clear sticky oil (2.5 mg, 76% yield).

¹H NMR (CDCl₃, 400 MHz) δ 1.00 (6H, m), 1.58 (4H, m), 1.78 (1H, m), 2.01-2.06 (2H, m), 2.15-2.19 (1H, m), 2.38-2.45 (1H, m), 2.54 (1H, m), 2.78 (1H, m), 3.44 (2H, dd, J=8, 12 Hz), 4.43 (2H, s), 7.19-7.23 (1H, m), 7.30-7.35 (4H, m), 7.56 (2H, s), 7.73 (1H, s). ¹³C NMR (CDCl₃, 100 MHz) δ 1.0, 10.1, 21.5, 29.7, 34.3, 44.4, 45.6, 45.9, 71.7, 81.2, 121.2 (quintet, J=4 Hz), 123.3 (q, J=271 Hz), 126.1, 126.9, 127.0 (d, J=4 Hz), 128.2, 131.4(q, J=34Hz), 140.3, 141.4. HPLC purity (retention time): 98% (1.85 min, method C). MS: 474.14 (MH⁺). HRMS calcd for C₂₅H₃₀NOF₆ 474.2232 (MH⁺), found 474.2243.

EXAMPLE 12 Isomer B of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-isopropyl-4-phenylazepane

¹H NMR (CDCl₃, 400 MHz) δ 1.00 (6H, m), 1.58 (4H, m), 1.78 (1H, m), 2.01-2.06 (2H, m), 2.15-2.19 (1H, m), 2.38-2.45 (1H, m), 2.54 (1H, m), 2.78 (1H, m), 3.44 (2H, dd, J=8, 12 Hz), 4.43 (2H, s), 7.19-7.23 (1H, m), 7.30-7.35 (4H, m), 7.56 (2H, s), 7.73 (1H, s). ¹³C NMR (CDCl₃, 100 MHz) δ 1.0, 10.1, 21.5, 29.7, 34.3, 44.4, 45.6, 45.9, 71.7, 81.2, 121.2 (quintet, J=4 Hz), 123.3 (q, J=271 Hz), 126.1, 126.9, 127.0 (d, J=4 Hz), 128.2, 131.4 (q, J=34 Hz), 140.3, 141.4. HPLC purity (retention time): 98% (1.83 min, method C). MS: 474.14 (MH⁺). HRMS calcd for C₂₅H₃₀NOF₆ 474.2232 (MH⁺), found 474.2242.

Examples 13 and 14 were made in the same manner as in Example 11.

EXAMPLE 13 Isomer A of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-cyclopentyl-4-phenylazepane

¹H NMR (CDCl₃, 400 MHz) δ 1.50 (5H, m), 1.66 (4H, m), 1.81 (3H, m), 2.02-2.07 (2H, m), 2.20 (1H, dd, J=8, 12 Hz), 2.40 (1H, m), 2.55 (1H, m), 2.83 (2H, m), 3.45 (2H, s), 4.44 (2H, s), 7.20-7.23 (1H, m), 7.30-7.35 (4H, m), 7.56 (2H, s), 7.73 (1H, s). HPLC purity (retention time): 90% (1.87 min, method C). MS: 500.19 (MH⁺). HRMS calcd for C₂₇H₃₂NOF₆ 500.2388 (MH⁺), found 500.2375.

EXAMPLE 14 Isomer B of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-cyclopentyl-4-phenylazepane

¹H NMR (CDCl₃, 400 MHz) δ 1.50 (5H, m), 1.66 (4H, m), 1.81 (3H, m), 2.02-2.07 (2H, m), 2.20 (1H, dd, J=8, 12 Hz), 2.40 (1H, m), 2.55 (1H, m), 2.83 (2H, m), 3.45 (2H, s), 4.44 (2H, s), 7.20-7.23 (1H, m), 7.30-7.35 (4H, m), 7.56 (2H, s), 7.73 (1H, s). HPLC purity (retention time): 90% (1.89 min, method C). MS: 500.13 (MH⁺). HRMS calcd for C₂₇H₃₂NOF₆ 500.2388 (MH⁺), found 500.2368.

NK-1 Binding Method

U373 cells, a human glioblastoma-astrocytoma cell line that endogenously express the neurokinin-1 (NK-1) receptor, were grown in a monolayer culture at 37° C. in 5% CO₂ and fed with Minimum Essential Medium (MEM) supplemented with 10% fetal bovine serum. Membranes were prepared as follows: Cells were washed twice with ice-cold phosphate-buffered saline (pH 7.4) and then incubated for 5 to 10 minutes with ice-cold 10 mM Tris buffer (pH 7.4) containing 5 mM EDTA. Cells were removed from plates, homogenized, and centrifuged at 32,000×g for 20 minutes. The resulting supernatant was discarded, and the pellet resuspended by homogenization in 50 mM Tris buffer (pH 7.4) containing 1 mM EDTA and centrifuged at 32,000×g for 20 minutes. The resulting supernatant was discarded, and the pellet resuspended by homogenization in NK-1 binding assay buffer (50 mM Tris-HCL (pH 7.4), 3 mM MnCl₂, 200 μg/ml BSA, 5 μg/ml chymostatin, 40 μg/ml bacitracin and 4 μg/ml leupeptin).

On the day of an experiment the membrane preparation was thawed, homogenized and diluted with NK-1 binding assay buffer to the appropriate concentration. Competition binding assays were performed in 96 well plate format by incubating membranes (5-10 ug/well) with Bolton Hunter labeled [¹²⁵I] Substance P, at a concentration of 200 nM, and concentrations of drugs ranging from 10000 to 0.01 nM. Samples were incubated for 30 min at 20° C. then filtered through GF/B glass fiber filters (pretreated with 1% polyethyleneimine and 0.3% Triton X-100) using a Brandel cell harvester. The filters were then washed with 10 ml ice cold 50 mM Tris-HCL (pH 7.4) containing 3 mM MgCl₂. Non-specific was defined in the presence of 2 μM L-733,060 (a non-peptide NK-1 antagonist). Amount of radioligand bound in the presence and absence of competitor was analyzed by plotting (−) log drug concentration versus the amount of radioligand specifically bound. The midpoint of the displacement curve (IC₅₀, nM), signifies the potency. K_(i) values were calculated using the method of Cheng and Prusoff [Cheng, Y.-C. and Prusoff, W. H., Biochemical Pharmacology, Vol. 22, pp. 3099-3108, Pergamon Press (1973)].

NK-1 antagonists have been recognized as useful agents for treating several diseases, e.g.: Chemotherapy-induced nausea and vomiting [Jeremy D. Gale, et al., Expert Opinion on Therapeutic Patents (2001), 11(12), 1837-1847]; Depression [S. Baby, et al., Journal of Clinical Pharmacy and Therapeutics (1999), 24(6), 461-469]; Depression and emesis [Nadia M. Rupniak, et al., Trends in Pharmacological Sciences (1999), 20(12), 485-490]; Treatment of human gliomas [Carla Palma, et al., Life Sciences (2000), 67(9), 985-1001]. Compounds of the present disclosure are NK-1 antagonists and may be useful for the treatment of depression, anxiety, obesity, psychosis, malignant gliomas, or in the control of chemotherapy-induced nausea and vomiting.

Serotonin Transporter Binding Assay

HEK-293 cells that stably express human serotonin transporters (HEK-hSERT cells) were grown at 37° C. in 5% CO₂ as a monolayer in medium consisting of EMEM supplemented with 10% fetal bovine serum and G418 sulfate (500 μg/ml). To prepare membranes for radioligand binding experiments, cells were rinsed twice with phosphate-buffered saline (138 mM NaCl, 4.1 mM KCl, 5.1 mM Na₂PO₄, 1.5 mM KH₂O₄, 11.1 mM glucose, pH 7.4). Cells were transferred from plates to polypropylene tubes (16×100 mm), centrifuged at 1,200×g for 5 min and were frozen at −80° C. until assay. Following centrifugation, pellets were resuspended by homogenization in buffer consisting of 50 mM Tris (pH 7.7 at 25° C.), 120 mM NaCl and 5 mM KCl and then centrifuged at 32,000×g for 10 min. Following centrifugation, supernatants were discarded and pellets were resuspended in buffer consisting of 50 mM Tris (pH 7.4 at 25° C.), 150 mM NaCl and 5 mM KCl. Membrane homogenates (200 μl/plate) were incubated with 1 nM [³H]-citalopram (specific activity=85 Ci/mmol) and increasing concentrations of test compounds for 1 hr at 25° C. in a total volume of 250 μl. The assay buffer consisted of 50 mM Tris (pH 7.4 at 25° C.), 120 mM NaCl and 5 mM KCl (pH 7.4 with conc. HCl). Plates were incubated for 1 hr at 25° C., then filtered through 0.5% PEI treated Whatman GF/B filters using a Brandel cell harvester. Filters were washed three times with 3 ml of ice-cold tris wash buffer. Non-specific binding was defined with 10 μM fluoxetine. Amount of radioligand bound in the presence and absence of competitor was analyzed by plotting (−) log drug concentration versus the amount of radioligand specifically bound. The midpoint of the displacement curve (IC₅₀, nm), signifies the potency. K_(i) values were calculated using the method of Cheng and Prusoff [Cheng, Y.-C. and Prusoff, W. H., Biochemical Pharmacology, Vol. 22, pp. 3099-3108, Pergamon Press (1973)].

NK-1 binding results are shown in Table I: TABLE I NK-1 SERT Example IC₅₀ IC₅₀ 1 *** *** 2 ** ** 3 *** ** 4 *** * 5 *** * 6 *** 7 *** * 8 *** 9 *** * 10 ** 12 *** 13 *** * 14 *** *** IC₅₀ < 20 nM; ** 20 nM < IC₅₀ < 100 nM; * 100 nM < IC₅₀ < 300 nM

As shown in Table 1, the compounds of Examples 1, 2, 3, 4, 5, 7, 9, and 13 have activity for both NK-1 and SERT. 

1. A compound of Formula (I)

or an isomer, a pharmaceutically acceptable salt or solvate thereof wherein R¹, R², R³, R⁴, R⁵ and R⁶ are independently H, C₁₋₄ alkyl, C₁₋₄ alkoxy, fluoro C₁₋₄ alkyl, halo or cyano; and R⁷ is H, C₁₋₆ alkyl, benzyl, C₃₋₆ cycloalkyl, or C₃₋₆ cycloalkyl C₁₋₃ alkyl.
 2. The compound of claim 1 wherein R⁷ is H.
 3. The compound of claim 1, wherein R⁴ and R⁵ are each CF₃ and R⁶ is H.
 4. The compound of claim 1 wherein R¹, R² and R³ are each hydrogen.
 5. The compound of claim 2 wherein R⁴ and R⁵ are each CF₃ and R⁶ is H.
 6. The compound of claim 5 wherein R¹, R² and R³ are each hydrogen.
 7. The compound of claim 6 wherein the absolute configuration is isomer A.
 8. The compound of Formula (I) according to claim 1, selected from the group consisting of: isomer A of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylazepane; isomer B of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-4-phenylazepane; isomer A of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-methyl-4-phenylazepane; isomer B of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-methyl-4-phenylazepane; isomer A of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-ethyl-4-phenylazepane; isomer B of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-ethyl-4-phenylazepane; isomer A of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-(cyclopropylmethyl)-4-phenylazepane; isomer A of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-benzyl-4-phenylazepane; isomer A of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-cyclopentyl-4-phenylazepane; isomer A of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-isopropyl-4-phenylazepane; isomer B of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-(cyclopropylmethyl)-4-phenylazepane; isomer B of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-cyclopentyl-4-phenylazepane; and isomer B of 4-((3,5-bis(trifluoromethyl)benzyloxy)methyl)-1-benzyl-4-phenylazepane.
 9. A pharmaceutical composition comprising a compound of claim 1, together with at least one pharmaceutically acceptable excipient.
 10. A method for the treatment or prevention of physiological disorders mediated by tachykinins and/or by the selective inhibition of the serotonin re-uptake transporter protein comprising administration of an effective amount of a compound according to claim
 1. 11. A method of treating a subject afflicted with a condition mediated by substance P and other neurokinins and/or by selective inhibition of the serotonin reuptake transporter protein comprising administration of an effective amount of a compound according to claim
 1. 12. A method for the treatment or prevention of depression and/or anxiety which method comprises administration to a patient in need of such treatment a therapeutically effective amount of a compound according to claim
 1. 